Macquarie Group Ltd. trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,658,143 shares of the healthcare product maker’s stock after selling 566,346 shares during the quarter. Abbott Laboratories accounts for 1.5% of Macquarie Group Ltd.’s investment portfolio, making the stock its 5th largest holding. Macquarie Group Ltd. owned 0.61% of Abbott Laboratories worth $770,904,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the company. Vestor Capital LLC raised its position in shares of Abbott Laboratories by 17.0% during the fourth quarter. Vestor Capital LLC now owns 247,212 shares of the healthcare product maker’s stock worth $17,881,000 after purchasing an additional 35,968 shares during the period. Western Wealth Management LLC purchased a new stake in Abbott Laboratories in the 4th quarter valued at $1,012,000. Cetera Advisors LLC raised its position in Abbott Laboratories by 3.7% in the 4th quarter. Cetera Advisors LLC now owns 28,644 shares of the healthcare product maker’s stock valued at $2,067,000 after buying an additional 1,014 shares during the last quarter. First Allied Advisory Services Inc. raised its position in Abbott Laboratories by 3.7% in the 4th quarter. First Allied Advisory Services Inc. now owns 43,630 shares of the healthcare product maker’s stock valued at $3,155,000 after buying an additional 1,569 shares during the last quarter. Finally, Mutual Advisors LLC raised its position in Abbott Laboratories by 1.3% in the 4th quarter. Mutual Advisors LLC now owns 15,564 shares of the healthcare product maker’s stock valued at $1,126,000 after buying an additional 206 shares during the last quarter. 75.17% of the stock is currently owned by institutional investors.
In other news, CFO Brian B. Yoor sold 2,246 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $78.00, for a total transaction of $175,188.00. Following the completion of the sale, the chief financial officer now directly owns 116,627 shares of the company’s stock, valued at approximately $9,096,906. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website . Also, Director John G. Stratton bought 3,455 shares of the firm’s stock in a transaction dated Thursday, January 31st. The shares were acquired at an average cost of $72.32 per share, with a total value of $249,865.60. Following the completion of the transaction, the director now owns 3,558 shares in the company, valued at $257,314.56. The disclosure for this purchase can be found here . Over the last ninety days, insiders have sold 280,021 shares of company stock valued at $20,485,856. Insiders own 0.70% of the company’s stock.
A number of research firms recently commented on ABT. Argus increased their price target on Abbott Laboratories to $90.00 and gave the company an “in-line” rating in a research report on Friday, January 25th. They noted that the move was a valuation call. Gabelli reissued a “buy” rating on shares of Abbott Laboratories in a research report on Wednesday, January 2nd. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $88.00 price target for the company in a research report on Tuesday, March 19th. Barclays set a $84.00 price target on Abbott Laboratories and gave the company a “buy” rating in a research report on Friday, March 8th. Finally, William Blair reissued an “outperform” rating on shares of Abbott Laboratories in a research report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $80.48.
Shares of Abbott Laboratories stock opened at $76.10 on Wednesday. Abbott Laboratories has a 1 year low of $56.81 and a 1 year high of $80.74. The firm has a market cap of $129.96 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 1.96 and a beta of 1.13. The company has a quick ratio of 1.20, a current ratio of 1.62 and a debt-to-equity ratio of 0.63.
Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.02. Abbott Laboratories had a return on equity of 16.91% and a net margin of 8.53%. The firm had revenue of $7.54 billion during the quarter, compared to analyst estimates of $7.49 billion. During the same period last year, the firm posted $0.59 EPS. The business’s revenue was up 2.0% compared to the same quarter last year. Equities analysts expect that Abbott Laboratories will post 3.21 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 1.68%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is presently 44.44%.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT) Receive News & Ratings for Abbott Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Macquarie Group Ltd. Lowers Stake in Abbott Laboratories (ABT)